Loading stock data…
Fate Therapeutics, Inc. (FATE)
$2.50+0.02 (+0.81%)
Market ClosedLast close Sep 8
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Fate Therapeutics, Inc. in the Healthcare sector is trading at $2.50 with a market capitalization of $259M. Wall Street consensus targets $5.74 (9 analysts), implying a +129.8% move over the next 12 months. The stock is currently 23% below its 52-week high of $3.23, remaining 44.5% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +129.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.30M↓ | $1.37M↓ | $1.74M↓ | $1.91M↑ | $1.63M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$33.00M↑ | -$34.72M | -$34.73M↑ | -$36.97M↑ | -$41.28M |
| Net Income | -$31.21M↑ | -$32.37M↓ | -$32.25M↑ | -$34.07M↑ | -$37.62M |
Peer Comparison
JNJUNHPFE
Fundamentals
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$258.76M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.14
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-72.29%
Volume
Today's trading volume
1.92M
Recent News
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of +10.71% and +108.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of -72.00% and -65.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials
The clearance allows the company to begin an early-stage basket trial in multiple autoimmune diseases later this year.
Sector Update: Healthcare Stocks Softer Late Afternoon
Healthcare stocks were lower late Thursday afternoon, with the NYSE Healthcare Index shedding 0.5% a